Evaluation of OCT2‐mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia

• Main Authors: Guangqing Xiao (Author), Hironobu Tsukada (Author), Yu‐Luan Chen (Author), Lei Shi (Author), Seth C. Hopkins (Author), Gerald R. Galluppi (Author)
• Format: Book
• Published: Wiley, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Ulotaront (SEP‐363856) is a TAAR1 agonist, with 5‐HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2‐specific inhibitor with IC50 of 1.27 μM. The primary objective of this study is to determine if a sin...